In Brief: Pharmavene
Pharmavene: Licenses Carbatrol (carbamazepine) anti-epileptic to Elan subsidiary Athena, which hopes to market Carbatrol to compete with Ciba's recently approved twice-daily tablet carbamazepine formulation Tegretol XR,, according to a July 5 IPO "red herring" prospectus. Pharmavene's NDA for its sustained-release capsule formulation of carbamazepine was submitted April 3. The proposed offering is for 2.2 mil. shares of common stock at an estimated price of $10-$12 per share...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth